US-based biopharmaceutical firm Gradalis has started a Phase III registration trial for its proprietary autologous immunotherapy, Vigil, to treat women with stage III/IV ovarian cancer.
The multicentre, randomised, double-blind, placebo-controlled, Phase III trial is being carried out in ovarian cancer patients who have been treated with primary cytoreduction and 5 to 6 cycles of standard of care chemotherapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company said that these patients will have had Vigil prepared and stored from ovarian tumour cells obtained at the time of initial surgical debulking.
Currently, there are no approved treatments for women with stage III/IV ovarian cancer.
The Phase III trial was rationalised based on a randomised Phase II trial, which showed efficacy, safety and immunological activity in the ovarian cancer patient population.
The results confirmed that Vigil was well tolerated with only mild, local injection-site adverse events.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition, about 93% of patients showed T-cell activation against their tumour antigen as early as one month after dosing of Vigil.
Gradalis president and chief executive officer Joseph Limber said: "The initiation of this trial demonstrates Gradalis’ significant advancement of our innovative, personalised immunotherapy which we believe has the potential to transform the way cancer is treated."
The trial forms the basis for the company’s personalised immunotherapy programme, and the ovarian cancer programme is the first of several development directions using this personalised immunotherapy.
Other programmes are being evaluated in the treatment of Ewing’s sarcoma, colorectal cancer with liver metastases, selected patients with non-small cell lung cancer as well as other solid tumours.
A patient’s tumour cells are engineered to secure a systemic T-cell directed immune response when Vigil is administered in monthly intradermal injections.
Vigil uses the patient’s own tumour as the antigen source to elicit an immune response that is both specifically targeted and broadly relevant to each patient’s tumour antigens.
Image: Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. Photo: courtesy of Nephron.
